Dapagliflozin (2S)-1,2-propanediol, hydrate is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in development for the treatment of type 2 diabetes mellitus (T2DM). It inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
Products > Drug Discovery > Impurities > Anti-Diabetic > Dapagliflozin and Impurities | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.